CR20230572A - Compuesto cíclico que contiene acción inhibidora selectiva en kras por sobre hras y nras - Google Patents

Compuesto cíclico que contiene acción inhibidora selectiva en kras por sobre hras y nras

Info

Publication number
CR20230572A
CR20230572A CR20230572A CR20230572A CR20230572A CR 20230572 A CR20230572 A CR 20230572A CR 20230572 A CR20230572 A CR 20230572A CR 20230572 A CR20230572 A CR 20230572A CR 20230572 A CR20230572 A CR 20230572A
Authority
CR
Costa Rica
Prior art keywords
kras
cyclic compound
hras
nras
compound
Prior art date
Application number
CR20230572A
Other languages
English (en)
Inventor
Satoshi Hashimoto
Minoru Tamiya
Kawada Hatsuo
Yuya Morita
Ryuji Hayashi
Koji Takano
Tomoya Kotake
Yuma Wakamiya
Mirai Kage
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of CR20230572A publication Critical patent/CR20230572A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se encontraron compuestos cíclicos y compuestos oligopéptidos que inhiben selectivamente a KRAS. También se encontraron compuestos oligopéptidos y aminoácidos no naturales útiles para producir un compuesto cíclico. Además, se encontró que los compuestos cíclicos y los compuestos oligopéptidos interactúan con un residuo de aminoácido específico de KRAS
CR20230572A 2021-05-07 2022-05-06 Compuesto cíclico que contiene acción inhibidora selectiva en kras por sobre hras y nras CR20230572A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2021079012 2021-05-07
PCT/JP2022/019544 WO2022234853A1 (ja) 2021-05-07 2022-05-06 Ｈｒａｓおよびｎｒａｓに対して選択的なｋｒａｓ阻害作用を有する環状化合物

Publications (1)

Publication Number Publication Date
CR20230572A true CR20230572A (es) 2024-01-25

Family

ID=83932768

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20230572A CR20230572A (es) 2021-05-07 2022-05-06 Compuesto cíclico que contiene acción inhibidora selectiva en kras por sobre hras y nras

Country Status (16)

Country Link
US (1) US20240158446A1 (es)
EP (1) EP4309741A1 (es)
JP (1) JPWO2022234853A1 (es)
KR (1) KR20240005777A (es)
CN (1) CN117279933A (es)
AR (1) AR125796A1 (es)
AU (1) AU2022268781A1 (es)
BR (1) BR112023022755A2 (es)
CA (1) CA3218182A1 (es)
CL (1) CL2023003137A1 (es)
CO (1) CO2023014807A2 (es)
CR (1) CR20230572A (es)
IL (1) IL307605A (es)
MX (1) MX2023013139A (es)
TW (1) TW202309063A (es)
WO (1) WO2022234853A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202406927A (zh) * 2022-05-06 2024-02-16 日商中外製藥股份有限公司 相對於ｈｒａｓ與ｎｒａｓ具有選擇性之ｋｒａｓ抑制作用的環狀化合物
CN115385867A (zh) * 2022-09-19 2022-11-25 安徽普利药业有限公司 一种氨基酸及其类似物的成环反应与开环方法
WO2024085235A1 (ja) * 2022-10-20 2024-04-25 中外製薬株式会社 環状ペプチドの結晶の製造方法
WO2024102421A2 (en) * 2022-11-09 2024-05-16 Revolution Medicines, Inc. Compounds, complexes, and methods for their preparation and of their use
WO2024101386A1 (ja) * 2022-11-09 2024-05-16 中外製薬株式会社 Ｈｒａｓおよびｎｒａｓに対して選択的なｋｒａｓ阻害作用を有する環状化合物
WO2024101402A1 (ja) * 2022-11-09 2024-05-16 中外製薬株式会社 Ｈｒａｓおよびｎｒａｓに対して選択的なｋｒａｓ阻害作用を有する環状化合物を含む医薬組成物
CN117567589B (zh) * 2023-04-23 2024-03-26 山东第一医科大学(山东省医学科学院) 一种具有抗菌活性的订书肽及其制备方法和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8987412B2 (en) 2011-03-04 2015-03-24 New York University Hydrogen bond surrogate macrocycles as modulators of Ras
EP3974563A1 (en) 2011-12-28 2022-03-30 Chugai Seiyaku Kabushiki Kaisha Cyclic peptides
WO2017181061A1 (en) 2016-04-15 2017-10-19 Ra Pharmaceuticals, Inc. Ras binding peptides and methods of use
CN110869544B (zh) 2017-06-09 2024-03-08 中外制药株式会社 膜透过性高的环状肽化合物及包含其的文库
JP7229158B2 (ja) 2017-06-09 2023-02-27 中外製薬株式会社 Ｎ－置換アミノ酸を含むペプチドの合成方法
CN118184532A (zh) * 2018-12-12 2024-06-14 中外制药株式会社 具有能形成分子内氢键的官能团的氨基酸、包含该氨基酸的肽化合物、及其制备方法
MX2022005302A (es) * 2019-11-07 2022-05-24 Chugai Pharmaceutical Co Ltd Compuesto de peptidos ciclicos que tiene accion inhibidora de kras.

Also Published As

Publication number Publication date
BR112023022755A2 (pt) 2024-01-02
JPWO2022234853A1 (es) 2022-11-10
CO2023014807A2 (es) 2023-11-20
US20240158446A1 (en) 2024-05-16
IL307605A (en) 2023-12-01
AR125796A1 (es) 2023-08-16
MX2023013139A (es) 2023-11-28
KR20240005777A (ko) 2024-01-12
CA3218182A1 (en) 2022-11-10
CN117279933A (zh) 2023-12-22
EP4309741A1 (en) 2024-01-24
WO2022234853A1 (ja) 2022-11-10
CL2023003137A1 (es) 2024-06-14
TW202309063A (zh) 2023-03-01
AU2022268781A1 (en) 2023-12-21

Similar Documents

Publication Publication Date Title
CR20230572A (es) Compuesto cíclico que contiene acción inhibidora selectiva en kras por sobre hras y nras
EP4043478A4 (en) CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITING ACTION
MX2022007527A (es) Inhibidores de proteinas kras mutantes.
EP4234781A3 (en) Knitted component
MX2022006609A (es) Compuesto de quinazolina que contiene anillo espiro.
AR117101A1 (es) Síntesis mejorada del intermedio clave del compuesto inhibidor de g12c de kras
MX2022001829A (es) Proceso de fabricación de moduladores de regulador de conductancia transmembrana de la fibrosis quística (cftr).
PH12019500493A1 (en) Solvate form of (r)-2-amino-3-phenylpropyl carbamate
MY197889A (en) Microorganism producing l-amino acid and method for producing l-amino acid using the same
ZA202109175B (en) Novel peptide compound or pharmaceutically acceptable salt thereof
MX2023010558A (es) Sintesis de omecamtiv mecarbil.
MX2022003974A (es) Sujeta cables.
MX2021009261A (es) Compuesto de fluorovinilbenzamida como inmunomodulador pd-l1.
MX2024000368A (es) Mezclas insecticidas.
MX2023004950A (es) Proceso para purificacion de pleuromutilinas.
MX2021009423A (es) Formas cristalinas de un inhibidor de la janocinasa 2 (jak2).
MX2022006383A (es) Procedimiento de purificacion de la hormona foliculo-estimulante.
JOP20220021A1 (ar) تخليق على مقياس العملية لمثبط كاليكرين في البلازما
MX2022001853A (es) Injerto gingival.
IL184519A0 (en) Protease inhibitor precursor synthesis
MX2021013726A (es) Butirato alimentario y sus usos.
MX2023000308A (es) Composicion, proceso y uso.
ZA202108637B (en) Microorganism for producing l-amino acid having increased cytochrome c activity, and l-amino acid production method using same
MX2020005168A (es) Formas de dosificacion que contienen un inhibidor calicreina de plasma.
MX2020009187A (es) Promotor novedoso y su uso.